Litcius/Paper detail

A validated LC-MS/MS method for determination of Molnupiravir and Favipiravir in human plasma; Assessment of the remarkable potential synergistic effect against SARS-CoV-2 Infection: Application to a pharmacokinetic study in healthy Egyptian volunteers

Hoda M. Marzouk, Amira S. Gouda, Mamdouh R. Rezk, Ahmed M. Abdel‐Megied

2023Microchemical Journal21 citationsDOI

Topics & Concepts

FavipiravirPharmacokineticsHuman plasmaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma concentrationRitonavirCoronavirus disease 2019 (COVID-19)Therapeutic drug monitoringChromatographyChemistryPharmacologyVirologyMedicineHuman immunodeficiency virus (HIV)Antiretroviral therapyViral loadPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAntibiotics Pharmacokinetics and EfficacyCOVID-19 Clinical Research Studies
A validated LC-MS/MS method for determination of Molnupiravir and Favipiravir in human plasma; Assessment of the remarkable potential synergistic effect against SARS-CoV-2 Infection: Application to a pharmacokinetic study in healthy Egyptian volunteers | Litcius